The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | CELESTIAL-TNCLL: ongoing Phase III study of sonrotoclax + zanubrutinib vs ven + obi for TN CLL
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, shares details of CELESTIAL-TNCLL (NCT06073821), an ongoing Phase III study comparing sonrotoclax plus zanubrutinib versus standard-of-care venetoclax (ven) plus obinutuzumab (obi) for treatment-naïve (TN) chronic lymphocytic leukemia (CLL). Dr Shadman hopes that combining sonrotoclax and zanubrutinib will confer a survival advantage and provide patients with a novel fixed-duration chemotherapy-free treatment option. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
